Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Allakos Inc | ALLK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.05 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.05 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.00 - 5.64 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.05 | USD |
Allakos Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 92.27M | 87.87M | - | 0 | -185.7M | -2.11 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Allakos News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALLK Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.04 | 1.12 | 1.02 | 1.06 | 344,580 | 0.01 | 0.96% |
| 1 Month | 1.32 | 1.36 | 1.02 | 1.16 | 425,263 | -0.27 | -20.45% |
| 3 Months | 1.31 | 1.69 | 1.02 | 1.30 | 679,349 | -0.26 | -19.85% |
| 6 Months | 1.80 | 3.405 | 1.00 | 1.70 | 1,140,191 | -0.75 | -41.67% |
| 1 Year | 4.55 | 5.64 | 1.00 | 2.65 | 1,095,693 | -3.50 | -76.92% |
| 3 Years | 108.54 | 114.38 | 1.00 | 9.52 | 1,309,992 | -107.49 | -99.03% |
| 5 Years | 39.31 | 157.98 | 1.00 | 20.80 | 922,101 | -38.26 | -97.33% |
Allakos Description
| Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. |
